Expanded Access to Rovalpituzumab Tesirine

AbbVie

Status

Conditions: Small Cell Lung Cancer

Treatments: Drug: rovalpituzumab tesirine

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03503890

C18-915

C19-917 (Other Grant/Funding Number)

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Rovalpituzumab Tesirine prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The participant must not be eligible for a Rovalpituzumab Tesirine clinical trial.
• Pediatric participants may be evaluated on a case by case basis.

Exclusion criteria

• None.